[go: up one dir, main page]

BR9807674A - Inibidores bicìclicos da proteìna farnesil transferase - Google Patents

Inibidores bicìclicos da proteìna farnesil transferase

Info

Publication number
BR9807674A
BR9807674A BR9807674-4A BR9807674A BR9807674A BR 9807674 A BR9807674 A BR 9807674A BR 9807674 A BR9807674 A BR 9807674A BR 9807674 A BR9807674 A BR 9807674A
Authority
BR
Brazil
Prior art keywords
pct
bicyclic
farnesyl transferase
protein inhibitors
transferase protein
Prior art date
Application number
BR9807674-4A
Other languages
English (en)
Inventor
Ellen Myra Dobrusin
Annette Marian Doherty
Dennis Joseph Mcnamara
Jack Bikker
Matthew Drowns
Marcin Stasiak
James Stanley Kaltenbronn
John Quin Iii
Joseph Thomas Repine
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9807674A publication Critical patent/BR9807674A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES BICìCLICOS DA PROTEìNA FARNESIL TRANSFERASE"<D>. A presente invenção fornece compostos de fórmula (I). A presente invenção também fornece um método de tratamento de câncer e tratamento ou prevenção de restenose ou ateroesclerose. Também é fornecido pela presente invenção uma composição farmaceuticamente aceitável contendo um composto de fórmula (I).
BR9807674-4A 1997-02-11 1998-02-11 Inibidores bicìclicos da proteìna farnesil transferase BR9807674A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3750497P 1997-02-11 1997-02-11
PCT/US1998/003025 WO1998034921A1 (en) 1997-02-11 1998-02-11 Bicyclic inhibitors of protein farnesyl transferase

Publications (1)

Publication Number Publication Date
BR9807674A true BR9807674A (pt) 2000-02-15

Family

ID=21894697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807674-4A BR9807674A (pt) 1997-02-11 1998-02-11 Inibidores bicìclicos da proteìna farnesil transferase

Country Status (13)

Country Link
US (3) US6133303A (pt)
EP (1) EP0966446B1 (pt)
JP (1) JP2001518076A (pt)
KR (1) KR20000070924A (pt)
AT (1) ATE307119T1 (pt)
AU (1) AU725696B2 (pt)
BR (1) BR9807674A (pt)
CA (1) CA2273895A1 (pt)
DE (1) DE69831937T2 (pt)
ES (1) ES2252827T3 (pt)
NZ (1) NZ336134A (pt)
WO (1) WO1998034921A1 (pt)
ZA (1) ZA981080B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR0110074A (pt) * 2000-04-17 2002-12-31 Warner Lambert Co Inibidores dihidro-2h-naftaleno-1-ona de ras farnesil transferase
MXPA02010098A (es) 2000-04-17 2003-02-12 Warner Lambert Co Tetralonas 5-substituidas como inhibidores de transferasa ras farnesil.
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20060004001A1 (en) * 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
US7550482B2 (en) * 2004-02-27 2009-06-23 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
CA2624731A1 (en) * 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington's disease
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
CN101932720A (zh) 2007-10-31 2010-12-29 米迪缪尼有限公司 蛋白质支架
CA2730280A1 (en) * 2008-07-10 2010-01-14 Southern Research Institute 5-quinolinone and imidazopyridine compounds and use thereof
US8725967B2 (en) * 2008-08-08 2014-05-13 Amazon Technologies, Inc. Providing executing programs with access to stored block data of others
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
EP2906598A1 (en) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
CN108064167A (zh) 2014-12-11 2018-05-22 皮埃尔法布雷医药公司 抗c10orf54抗体及其用途
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN105801421A (zh) * 2016-03-31 2016-07-27 常州大学 一种2-醛基-3-羟基-4,6-二氯苯甲酸的合成方法
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
EP3694889A1 (en) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Human antibodies to thomsen-nouvelle (tn) antigen
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535225A (de) * 1969-03-29 1973-03-31 Schering Ag Verfahren zur Herstellung von heterocyclischen Nitroverbindungen
DE1937630A1 (de) * 1969-07-19 1971-02-04 Schering Ag 2-(5-Nitro-2-furfuryliden)-l-tetralone
JPS6013788A (ja) * 1983-07-05 1985-01-24 Yamanouchi Pharmaceut Co Ltd 新規なクマリン誘導体
BR8305086A (pt) 1983-09-19 1984-03-20 Antonio Signori Dispositivo de amortecimento aplicavel a calcados em geral
ES539074A0 (es) * 1984-12-10 1985-11-16 Ferrer Int Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos.
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
US5149703A (en) * 1991-09-06 1992-09-22 Merck Frosst Canada, Inc. Quinoline-substituted chromans and related compounds as leukotriene antagonists
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
PL308474A1 (en) * 1992-10-21 1995-08-07 Pfizer Sulphonamidic derivatives of hydroxy substituted cycloalkylic and heterocyclic compounds with condensed benzene ring
JPH10510510A (ja) * 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
EP0695753A1 (en) * 1994-08-05 1996-02-07 Zeneca Limited Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA969273B (en) * 1995-11-06 1998-05-05 Univ Pittsburgh Inhibitors of protein isoprenyl transferases.
AU704087B2 (en) * 1996-01-30 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250460A1 (en) * 1996-04-03 1997-10-09 John H. Hutchinson Inhibitors of farnesyl-protein transferase
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU9452998A (en) * 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6403581B1 (en) * 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives

Also Published As

Publication number Publication date
US6265422B1 (en) 2001-07-24
DE69831937D1 (de) 2006-03-02
JP2001518076A (ja) 2001-10-09
AU725696B2 (en) 2000-10-19
ES2252827T3 (es) 2006-05-16
DE69831937T2 (de) 2006-07-27
ZA981080B (en) 1998-08-12
EP0966446A1 (en) 1999-12-29
AU6170498A (en) 1998-08-26
KR20000070924A (ko) 2000-11-25
ATE307119T1 (de) 2005-11-15
US20020006936A1 (en) 2002-01-17
EP0966446B1 (en) 2005-10-19
US6528535B2 (en) 2003-03-04
NZ336134A (en) 2001-08-31
US6133303A (en) 2000-10-17
CA2273895A1 (en) 1998-08-13
WO1998034921A1 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
DE69516866D1 (de) Stereochemische wortmanninderivate
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
UA29446C2 (uk) Засіб для інгібування тромбіну
NO996578L (no) Urokinase-inhibitorer
MX9602861A (es) Mezcla estabilizante sinergistica.
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
MX9801190A (es) Inhibidores de prolil endopeptidasa.
PL317349A1 (en) Organic compounds
NO952427L (no) Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5
BR9906803A (pt) Processo para tratamento de copd
SE9704770D0 (sv) New use
PL318539A1 (en) Inhibition of biosynthesis
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
IT1265256B1 (it) 4-alchil e 4-alchenil delta-3-cefem solfoni
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
RO116896B1 (ro) Derivaţi pseudocarbaciclinici şi procedeu pentru prepararea acestora

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.

B15K Others concerning applications: alteration of classification

Ipc: C07D 233/64 (2006.01), C07D 231/12 (2006.0